Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma

Jinu Abraham, Suresh I. Prajapati, Koichi Nishijo, Beverly S. Schaffer, Eri Taniguchi, Aoife Kilcoyne, Amanda T. McCleish, Laura D. Nelon, Francis G. Giles, Argiris Efstratiadis, Robin D. LeGallo, Brent M. Nowak, Brian P. Rubin, Suman Malempati, Charles Keller

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Inhibition of the insulin-like growth factor 1 receptor (Igf1r) is an approach being taken in clinical trials to overcome the dismal outcome for metastatic alveolar rhabdomyosarcoma (ARMS), an aggressive muscle cancer of children and young adults. In our study, we address the potential mechanism(s) of Igf1r inhibitor resistance that might be anticipated for patients. Using a genetically engineered mouse model of ARMS, validated for active Igf1r signaling, we show that the prototypic Igf1r inhibitor NVP-AEW541 can inhibit cell growth and induce apoptosis in vitro in association with decreased Akt and Mapk phosphorylation. However, drug resistance in vivo is more common and is accompanied by Igf1r overexpression, Mapk reactivation, and Her2 overexpression. Her2 is found to form heterodimers with Igf1r in resistant primary tumor cell cultures, and stimulation with Igf2 leads to Her2 phosphorylation. The Her2 inhibitor lapatinib cooperates with NVP-AEW541 to reduce Igf1r phosphorylation and to inhibit cell growth even though lapatinib alone has little effect on growth. These results point to the potential therapeutic importance of simultaneous targeting of Igf1r and Her2 to abrogate resistance.

Original languageEnglish (US)
Pages (from-to)697-707
Number of pages11
JournalMolecular Cancer Therapeutics
Volume10
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Somatomedin Receptors
Rhabdomyosarcoma
Alveolar Rhabdomyosarcoma
Phosphorylation
Growth
Muscle Neoplasms
Primary Cell Culture
Drug Resistance
Young Adult
Clinical Trials
Apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Abraham, J., Prajapati, S. I., Nishijo, K., Schaffer, B. S., Taniguchi, E., Kilcoyne, A., ... Keller, C. (2011). Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Molecular Cancer Therapeutics, 10(4), 697-707. https://doi.org/10.1158/1535-7163.MCT-10-0695

Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. / Abraham, Jinu; Prajapati, Suresh I.; Nishijo, Koichi; Schaffer, Beverly S.; Taniguchi, Eri; Kilcoyne, Aoife; McCleish, Amanda T.; Nelon, Laura D.; Giles, Francis G.; Efstratiadis, Argiris; LeGallo, Robin D.; Nowak, Brent M.; Rubin, Brian P.; Malempati, Suman; Keller, Charles.

In: Molecular Cancer Therapeutics, Vol. 10, No. 4, 04.2011, p. 697-707.

Research output: Contribution to journalArticle

Abraham, J, Prajapati, SI, Nishijo, K, Schaffer, BS, Taniguchi, E, Kilcoyne, A, McCleish, AT, Nelon, LD, Giles, FG, Efstratiadis, A, LeGallo, RD, Nowak, BM, Rubin, BP, Malempati, S & Keller, C 2011, 'Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma', Molecular Cancer Therapeutics, vol. 10, no. 4, pp. 697-707. https://doi.org/10.1158/1535-7163.MCT-10-0695
Abraham J, Prajapati SI, Nishijo K, Schaffer BS, Taniguchi E, Kilcoyne A et al. Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Molecular Cancer Therapeutics. 2011 Apr;10(4):697-707. https://doi.org/10.1158/1535-7163.MCT-10-0695
Abraham, Jinu ; Prajapati, Suresh I. ; Nishijo, Koichi ; Schaffer, Beverly S. ; Taniguchi, Eri ; Kilcoyne, Aoife ; McCleish, Amanda T. ; Nelon, Laura D. ; Giles, Francis G. ; Efstratiadis, Argiris ; LeGallo, Robin D. ; Nowak, Brent M. ; Rubin, Brian P. ; Malempati, Suman ; Keller, Charles. / Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. In: Molecular Cancer Therapeutics. 2011 ; Vol. 10, No. 4. pp. 697-707.
@article{309fa3518c8745cd9d3a211f0598c5f3,
title = "Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma",
abstract = "Inhibition of the insulin-like growth factor 1 receptor (Igf1r) is an approach being taken in clinical trials to overcome the dismal outcome for metastatic alveolar rhabdomyosarcoma (ARMS), an aggressive muscle cancer of children and young adults. In our study, we address the potential mechanism(s) of Igf1r inhibitor resistance that might be anticipated for patients. Using a genetically engineered mouse model of ARMS, validated for active Igf1r signaling, we show that the prototypic Igf1r inhibitor NVP-AEW541 can inhibit cell growth and induce apoptosis in vitro in association with decreased Akt and Mapk phosphorylation. However, drug resistance in vivo is more common and is accompanied by Igf1r overexpression, Mapk reactivation, and Her2 overexpression. Her2 is found to form heterodimers with Igf1r in resistant primary tumor cell cultures, and stimulation with Igf2 leads to Her2 phosphorylation. The Her2 inhibitor lapatinib cooperates with NVP-AEW541 to reduce Igf1r phosphorylation and to inhibit cell growth even though lapatinib alone has little effect on growth. These results point to the potential therapeutic importance of simultaneous targeting of Igf1r and Her2 to abrogate resistance.",
author = "Jinu Abraham and Prajapati, {Suresh I.} and Koichi Nishijo and Schaffer, {Beverly S.} and Eri Taniguchi and Aoife Kilcoyne and McCleish, {Amanda T.} and Nelon, {Laura D.} and Giles, {Francis G.} and Argiris Efstratiadis and LeGallo, {Robin D.} and Nowak, {Brent M.} and Rubin, {Brian P.} and Suman Malempati and Charles Keller",
year = "2011",
month = "4",
doi = "10.1158/1535-7163.MCT-10-0695",
language = "English (US)",
volume = "10",
pages = "697--707",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma

AU - Abraham, Jinu

AU - Prajapati, Suresh I.

AU - Nishijo, Koichi

AU - Schaffer, Beverly S.

AU - Taniguchi, Eri

AU - Kilcoyne, Aoife

AU - McCleish, Amanda T.

AU - Nelon, Laura D.

AU - Giles, Francis G.

AU - Efstratiadis, Argiris

AU - LeGallo, Robin D.

AU - Nowak, Brent M.

AU - Rubin, Brian P.

AU - Malempati, Suman

AU - Keller, Charles

PY - 2011/4

Y1 - 2011/4

N2 - Inhibition of the insulin-like growth factor 1 receptor (Igf1r) is an approach being taken in clinical trials to overcome the dismal outcome for metastatic alveolar rhabdomyosarcoma (ARMS), an aggressive muscle cancer of children and young adults. In our study, we address the potential mechanism(s) of Igf1r inhibitor resistance that might be anticipated for patients. Using a genetically engineered mouse model of ARMS, validated for active Igf1r signaling, we show that the prototypic Igf1r inhibitor NVP-AEW541 can inhibit cell growth and induce apoptosis in vitro in association with decreased Akt and Mapk phosphorylation. However, drug resistance in vivo is more common and is accompanied by Igf1r overexpression, Mapk reactivation, and Her2 overexpression. Her2 is found to form heterodimers with Igf1r in resistant primary tumor cell cultures, and stimulation with Igf2 leads to Her2 phosphorylation. The Her2 inhibitor lapatinib cooperates with NVP-AEW541 to reduce Igf1r phosphorylation and to inhibit cell growth even though lapatinib alone has little effect on growth. These results point to the potential therapeutic importance of simultaneous targeting of Igf1r and Her2 to abrogate resistance.

AB - Inhibition of the insulin-like growth factor 1 receptor (Igf1r) is an approach being taken in clinical trials to overcome the dismal outcome for metastatic alveolar rhabdomyosarcoma (ARMS), an aggressive muscle cancer of children and young adults. In our study, we address the potential mechanism(s) of Igf1r inhibitor resistance that might be anticipated for patients. Using a genetically engineered mouse model of ARMS, validated for active Igf1r signaling, we show that the prototypic Igf1r inhibitor NVP-AEW541 can inhibit cell growth and induce apoptosis in vitro in association with decreased Akt and Mapk phosphorylation. However, drug resistance in vivo is more common and is accompanied by Igf1r overexpression, Mapk reactivation, and Her2 overexpression. Her2 is found to form heterodimers with Igf1r in resistant primary tumor cell cultures, and stimulation with Igf2 leads to Her2 phosphorylation. The Her2 inhibitor lapatinib cooperates with NVP-AEW541 to reduce Igf1r phosphorylation and to inhibit cell growth even though lapatinib alone has little effect on growth. These results point to the potential therapeutic importance of simultaneous targeting of Igf1r and Her2 to abrogate resistance.

UR - http://www.scopus.com/inward/record.url?scp=79955779350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955779350&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0695

DO - 10.1158/1535-7163.MCT-10-0695

M3 - Article

VL - 10

SP - 697

EP - 707

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -